Side Effects for PE Amid Changing EU Life Sciences and Healthcare Landscape

October 20, 2023

Substantial changes to the European life sciences and healthcare regulatory landscape are expected to reshape the sector. EU regulators have outlined a raft of reforms to modernise regulatory architecture, simplify product approval processes, enhance patient safety, and improve access to innovative health products….
By: Latham & Watkins LLP

Side Effects for PE Amid Changing EU Life Sciences and Healthcare Landscape

Recent FDA Initiatives to Support Development of Individualized Cell and Gene Therapies and Rare Disease Therapies

2023 Proxy Season Results in Silicon Valley and Large Companies Nationwide